94994-15-7

Basic information

• Product Name: Methyl 4-(hydroxyMethyl)bicyclo[2.2.2]octane-1-carboxylate
• Synonyms: Methyl 4-(hydroxyMethyl)bicyclo[2.2.2]octane-1-carboxylate;4-HydroxyMethyl-bicyclo[2.2.2]octane-1-carboxylic acid Methyl ester
• CAS NO: 94994-15-7
• Molecular Formula: C₁₁H₁₈O₃
• Molecular Weight: 198.25882
• Mol File: 94994-15-7.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 274.1°C at 760 mmHg
• Flash Point: 108.7°C
• Appearance: /
• Density: 1.175g/cm³
• Vapor Pressure: 0.000704mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 4-(hydroxyMethyl)bicyclo[2.2.2]octane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(hydroxyMethyl)bicyclo[2.2.2]octane-1-carboxylate(94994-15-7)
• EPA Substance Registry System: Methyl 4-(hydroxyMethyl)bicyclo[2.2.2]octane-1-carboxylate(94994-15-7)

Safety Data

• Hazardous Substances Data: 94994-15-7(Hazardous Substances Data)

Usage

General Description

Methyl 4-(hydroxyMethyl)bicyclo[2.2.2]octane-1-carboxylate is a chemical compound with the molecular formula C11H18O4. It is a bicyclic compound containing a tertiary alcohol and an ester functional group. This chemical is commonly used as a fragrance ingredient in perfumes and cosmetic products due to its pleasant odor. It is also used in the pharmaceutical industry as a building block for the synthesis of various organic compounds. This chemical is stable under normal conditions and is not known to be harmful when used in accordance with safety guidelines.

InChI:InChI=1/C11H18O3/c1-14-9(13)11-5-2-10(8-12,3-6-11)4-7-11/h12H,2-8H2,1H3

Upstream product

• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 54774-94-6 4-acetoxybicyclo<2.2.2>octan-1-ol 
• 711-02-4 1,4-bicyclo[2.2.2]octanedicarboxylic acid 
• 10364-35-9 1,4-Diacetoxybicyclo<2.2.2>octane 
• 4982-20-1 1,4-dimethylidenecyclohexane 
• 1459-96-7 dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate 
• 1194-44-1 1,4-dihydroxybicyclo[2.2.2]octane 
• 541-41-3 chloroformic acid ethyl ester 
• 953-69-5 4-phenylbicyclo<2.2.2>octane-1-carboxylic acid 
• 23062-52-4 methyl 4-phenylbicyclo<2.2.2>octane-1-carboxylate 
• 94-60-0 dimethyl 1,4-cyclohexane dicarboxylate 

Downstream Products

• 1434364-70-1 C₂₄H₃₃NO₅ 
• 959958-69-1 3-(4-(6-amino-2,4-dioxo-1-propyl-3-heptadeuteriopropyl-1,2,3,4-tetrahydro-pyrimidin-5-ylcarbamoyl)-bicyclo[2.2.2]oct-1-yl)propionic acid methyl ester 
• 96102-85-1 4-formyl-bicyclo[2.2.2]octane-1-carboxylic acid 
• 94994-25-9 4-carbomethoxybicyclo<2.2.2>octane-1-carboxaldehyde 
• 828-52-4 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylic acid 

Relevant articles and documents

MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF

Disclosed herein are compounds, compositions, and methods for modulating the monocarboxylic acid transporter 4 (MCT4) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.